JP2007522096A5 - - Google Patents

Download PDF

Info

Publication number
JP2007522096A5
JP2007522096A5 JP2006533638A JP2006533638A JP2007522096A5 JP 2007522096 A5 JP2007522096 A5 JP 2007522096A5 JP 2006533638 A JP2006533638 A JP 2006533638A JP 2006533638 A JP2006533638 A JP 2006533638A JP 2007522096 A5 JP2007522096 A5 JP 2007522096A5
Authority
JP
Japan
Prior art keywords
epha4
antibody
antibodies
scfv
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006533638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/018279 external-priority patent/WO2005048917A2/en
Publication of JP2007522096A publication Critical patent/JP2007522096A/ja
Publication of JP2007522096A5 publication Critical patent/JP2007522096A5/ja
Abandoned legal-status Critical Current

Links

JP2006533638A 2003-06-06 2004-06-07 癌の診断、治療、及び予防のためのＥｐｈＡ４及びＥｐｈＡ４変調因子の使用 Abandoned JP2007522096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47690903P 2003-06-06 2003-06-06
US50335603P 2003-09-16 2003-09-16
PCT/US2004/018279 WO2005048917A2 (en) 2003-06-06 2004-06-07 Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer

Publications (2)

Publication Number Publication Date
JP2007522096A JP2007522096A (ja) 2007-08-09
JP2007522096A5 true JP2007522096A5 (https=) 2008-06-19

Family

ID=34622735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533638A Abandoned JP2007522096A (ja) 2003-06-06 2004-06-07 癌の診断、治療、及び予防のためのＥｐｈＡ４及びＥｐｈＡ４変調因子の使用

Country Status (7)

Country Link
US (2) US7604799B2 (https=)
EP (1) EP1638514A4 (https=)
JP (1) JP2007522096A (https=)
KR (1) KR20060034231A (https=)
AU (1) AU2004291026A1 (https=)
CA (1) CA2528549A1 (https=)
WO (1) WO2005048917A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US9032097B2 (en) * 2001-04-26 2015-05-12 Nokia Corporation Data communication with remote network node
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1606305A4 (en) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
KR20060034231A (ko) * 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
DK1730196T3 (da) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US20070128116A1 (en) * 2005-07-27 2007-06-07 Wang Zheng J Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs
US7807459B2 (en) * 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
AU2006331775A1 (en) * 2005-12-21 2007-07-05 Medimmune, Llc Affinity optimized EphA2 agonistic antibodies and methods of use thereof
US8003098B2 (en) 2006-02-28 2011-08-23 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-EphA4 antibodies
CA2696164C (en) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
US20100256214A1 (en) * 2009-04-02 2010-10-07 Burnham Institute For Medical Research Eph receptor ligands and methods of use
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2012078703A2 (en) * 2010-12-08 2012-06-14 Fox Chase Cancer Center Inhibiting chromosome instability in ovarian cancer
NZ611428A (en) * 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
JP5961608B2 (ja) * 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
JP6811706B2 (ja) * 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
EA201792380A1 (ru) * 2015-04-29 2018-04-30 Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
CN108108589B (zh) * 2017-12-29 2020-06-12 郑州轻工业学院 基于网络指标差异分析的食管鳞癌标记物的识别方法
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
US20230203096A1 (en) * 2020-04-23 2023-06-29 The Regents Of The University Of California Epha4 targeting compounds and methods of use thereof
US11732007B2 (en) 2020-09-28 2023-08-22 The Regents Of The University Of California Therapeutic compounds and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224374A (en) * 1880-02-10 Extension-ladder
US28685A (en) * 1860-06-12 Peed-water apparatus for steam-boilers
US622711A (en) * 1899-04-11 render
US503356A (en) * 1893-08-15 Wire-netting machine
US180823A (en) * 1876-08-08 Improvement in farm-gates
US476909A (en) * 1892-06-14 Rail-cleaning attachment for cars
US952560A (en) * 1909-06-28 1910-03-22 Gewerkschaft Der Stein Kohlenzeche Mont Cenis Process of obtaining ammonium sulfate from gases.
FI85768C (fi) 1990-07-04 1992-05-25 Valtion Teknillinen Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare.
DE69110032T2 (de) 1991-06-08 1995-12-21 Hewlett Packard Gmbh Verfahren und Gerät zur Feststellung und/oder Konzentrationsbestimmung von Biomolekülen.
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
JP2002518663A (ja) 1998-05-20 2002-06-25 グラッフィニティ ファルマシューティカル デザイン ゲーエムベーハー 液体状態で存在する多数の試料を同時に測定するためのｓｐｒセンサー
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
AU5761900A (en) * 1999-06-30 2001-01-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2411601A1 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US20020025536A1 (en) * 2000-06-26 2002-02-28 Jeno Gyuris Methods and reagents for isolating biologically active antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1410011B1 (en) 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
AU2003268345A1 (en) 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
KR20060034231A (ko) * 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES

Similar Documents

Publication Publication Date Title
JP2007522096A5 (https=)
CN113227135B (zh) 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
US20230192851A1 (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
EP3653644B1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
CN112601544A (zh) 人类抗cd47抗体及其用途
AU2013302620B2 (en) Stem cell enhancing therapeutics
CA2777691A1 (en) Monoclonal antibodies to progastrin and their uses
CA2706529A1 (en) Anti-mesothelin antibodies and uses therefor
CA2759836A1 (en) Humanized axl antibodies
CA2786479A1 (en) Methods for treating pancreatic cancer
US11401343B2 (en) Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same
EP3689908A2 (en) Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
US10752688B2 (en) Anti-human TIM-3 antibodies and methods of use thereof
EP4101472A1 (en) Anti-meflin antibody for use in treatment cancer in subject having cancer, and pharmaceutical composition including said antibody
CN109384845B (zh) 一种cd40单克隆抗体、其制备方法及其应用
EP2270053A1 (en) Humanized AXL antibodies
EP3137909B1 (en) Diagnostic anti-cd95l antibody
CN118108842A (zh) 人源化抗cd24抗体及其应用
CN114380913B (zh) 一种全人源抗pd-l1抗体及其应用
WO2026068571A1 (en) Lrg1 antigen-binding molecules
JP2022523750A (ja) 抗－ｆｇｆ１９抗体
HK1231096A1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HK1231096B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer